References

FULL PAGE CONTENT

This page provides a source hub for the medical and regulatory information used throughout Lorbrexen.com.

Regulatory sources

U.S. Food and Drug Administration — LORBRENA

The current U.S. label provides information on indication, dosage, contraindications, warnings, adverse reactions, interactions and special populations.

DailyMed — LORBRENA

DailyMed provides the current structured U.S. labeling record for LORBRENA.

European Medicines Agency — Lorviqua

The EMA provides European authorization and product information for Lorviqua, including the current therapeutic indication and marketing authorization details.

Clinical evidence

The CROWN study is a major source of evidence for first-line lorlatinib treatment in advanced ALK-positive NSCLC. The five-year results were published in the Journal of Clinical Oncology.

A seven-year update was presented at the 2026 ASCO Annual Meeting and reported in the Journal of Clinical Oncology supplement.

Manufacturer and development sources

Pfizer describes lorlatinib as a medicine discovered and developed by Pfizer scientists.

Lorbrexen-specific sources

The manufacturer, authorization status and product-specific regulatory documentation for Lorbrexen are Everest Pharmaceuticals Ltd.

Reference categories